Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 3, 2026
The marker that fails first — and gets tested last There is a specific sequence to how metabolic disease unfolds, and almost nobody gets to watch it happen. By the time the standard markers move, the disease is years old. Here is the order of events. First, your cells become resistant to insulin's signal. Second, your pancreas compensates by pumping out more insulin to force glucose into those…
This dispatch covers Your Fasting Insulin Is the Number Your Doctor Never Ordered — And It Breaks Years Before Your Glucose in the research research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 7 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
There is a specific sequence to how metabolic disease unfolds, and almost nobody gets to watch it happen. By the time the standard markers move, the disease is years old.
Here is the order of events. First, your cells become resistant to insulin's signal. Second, your pancreas compensates by pumping out more insulin to force glucose into those resistant cells. Third — and only third, sometimes a decade later — the pancreas can no longer keep up, and your fasting glucose and HbA1c finally drift out of range. That is the moment your annual physical notices something is wrong.
The problem is that the entire compensation phase — the years where your insulin is climbing to hold the line — is invisible to a standard panel. Fasting glucose looks fine. HbA1c looks fine. You are told you are fine.
You are not fine. You are compensating. And the single number that would show it — fasting insulin — is almost never on the order.
This is the next entry in our running series on the markers your physical leaves out. We have covered GGT, ferritin, uric acid, ApoB, homocysteine, and the rest of the "normal but actually broken" cluster. Fasting insulin may be the most consequential omission of all, because it is the earliest leading indicator of the most common chronic disease in the developed world.
Glucose tells you how much sugar is in the blood right now. Insulin tells you how hard your body is working to keep it there.
Two people can have an identical fasting glucose of 92 mg/dL. One has a fasting insulin of 3 µIU/mL — their cells hear the signal, very little insulin is needed, the system is efficient. The other has a fasting insulin of 18 µIU/mL — same glucose, but it is taking six times the hormonal effort to achieve it. The first person is metabolically healthy. The second is in the middle of the silent compensation phase, and a glucose-only panel cannot tell them apart.
That gap is the entire argument for measuring insulin directly.
You can combine fasting glucose and fasting insulin into a single index called HOMA-IR (Homeostatic Model Assessment of Insulin Resistance). The math is simple enough to do on a napkin:
HOMA-IR = (fasting insulin µIU/mL × fasting glucose mg/dL) ÷ 405
A practical reading of the ranges used in functional and research settings:
| HOMA-IR | Interpretation |
|---|---|
| < 1.0 | Optimal insulin sensitivity |
| 1.0 – 1.9 | Early/borderline — worth watching |
| 2.0 – 2.9 | Significant insulin resistance |
| ≥ 3.0 | Marked insulin resistance |
Note what HOMA-IR does that neither number does alone: it catches the person with normal glucose and high insulin. Their glucose multiplier is unremarkable, but the insulin term drags the index up — which is exactly the population a glucose-only screen misses.
When fasting insulin is run, most labs report a reference range of roughly 2.6 to 24.9 µIU/mL. That ceiling is the trap.
A reference range is a statistical description of the middle 95% of the people the lab tested. It is not a health target. And in a population where insulin resistance is widespread, the "normal" range is normalizing the disease — the upper end of that interval is populated by people who are already deep into compensation. Being inside the range means you resemble the average tested adult. It does not mean your metabolism is working.
Most functional clinicians anchor to a far tighter optimal band — roughly 2 to 6 µIU/mL fasting — because that is where insulin sensitivity, not mere survival-of-the-population, actually sits. A fasting insulin of 18 is comfortably "in range" on the lab report and simultaneously a five-alarm signal that the pancreas is working overtime.
The case for fasting insulin as an early predictor of type 2 diabetes is strong and old. Landmark prospective work, including the San Antonio Heart Study, established decades ago that hyperinsulinemia precedes and predicts the onset of type 2 diabetes — the insulin climbs years before the glucose does. That is the central claim of this article, and it is well supported.
It is worth being precise about a second claim, because honesty about the evidence is the whole point of this publication. The relationship between insulin resistance and cardiovascular outcomes is real but more nuanced than the diabetes link. According to PubMed, the PROSPER long-term follow-up (Welsh et al., Diabetologia, 2014) found that higher HOMA-IR strongly predicted incident diabetes in older adults — roughly a fivefold increase comparing the highest to lowest third — yet in that elderly cohort it was not independently associated with cardiovascular events or all-cause mortality once other factors were accounted for (DOI). The lesson is not that insulin resistance is harmless to the heart; it travels with ApoB, triglycerides, blood pressure, and inflammation, which carry their own risk. The lesson is that fasting insulin earns its place on a panel primarily as the earliest metabolic warning system — not as a standalone cardiac crystal ball.
The reason it works so well as an early system is mechanistic. Insulin resistance is upstream of the rest of the cluster. According to PubMed, a meta-analysis of fiber interventions in diabetes (Reynolds et al., PLoS Medicine, 2020) showed that raising dietary fiber measurably lowered fasting insulin and HOMA-IR alongside triglycerides, LDL, body weight, and C-reactive protein — improvements that moved together (DOI). That co-movement is the tell: insulin resistance is not an isolated lab value, it is the hub the other metabolic markers rotate around.
Across this series, the same cluster keeps reassembling itself from different starting markers:
Fasting insulin > 8 + triglycerides > 100 + HDL < 50 + GGT 30–50 + ferritin > 200 = a metabolic syndrome signature that a normal fasting glucose and a normal HbA1c will completely hide.
Every one of those markers can be individually waved off as "in range." Stacked, they describe a metabolism that is years into a trajectory. Fasting insulin is the one that usually fires first — which is precisely why leaving it off the panel costs you the early-warning window.
A useful triglyceride-to-HDL ratio sits alongside this: a ratio above ~3 (or above ~2 using mg/dL in many populations) is a crude but free proxy for insulin resistance you can read off a basic lipid panel you may already have. It is not a substitute for measuring insulin directly, but if your physical already ran a lipid panel, you can do that division today and get a rough read before you ever order a new test.
Three practical takeaways:
Ask for fasting insulin by name. It is rarely included by default. The test is inexpensive and widely available; it is simply not ordered. Pair it with the fasting glucose you almost certainly already have so you can compute HOMA-IR.
Judge it against the optimal band, not the lab ceiling. Aim to understand where you sit relative to ~2–6 µIU/mL, not whether you cleared the lab's ~25 ceiling. "In range" and "optimal" are different questions.
Read it as part of the cluster. A single insulin value is informative; insulin plus triglycerides plus HDL plus GGT plus ferritin is a diagnosis-shaped pattern. The markers confirm each other.
The frustration so many people describe — "everything came back normal, but I don't feel normal" — is frequently this exact gap. The compensation phase is real, it is measurable, and it has a number. Fasting insulin is that number. Your physical just isn't ordering it.
Educational content only. This article describes biomarkers and published research and is not medical advice, diagnosis, or treatment. Reference and optimal ranges vary by laboratory and individual; interpret any lab value with a qualified clinician.
Research referenced via PubMed: Welsh et al., Diabetologia, 2014 (DOI); Reynolds et al., PLoS Medicine, 2020 (DOI). The San Antonio Heart Study findings on hyperinsulinemia preceding type 2 diabetes are part of the long-standing prospective literature on insulin resistance.
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.